[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-354274-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-354274-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","safety-tolerability-and-pharmacokinetics-of-mirvetuximab-soravtansine-in-chinese-patients-with-folate-receptor-positive-advanced-ovarian-cancer","Safety, Tolerability, and Pharmacokinetics of Mirvetuximab Soravtansine in Chinese Patients With Folate Receptor α-Positive Advanced Ovarian Cancer","","Folate receptor α (FRα) is identified as a promising therapeutic target in ovarian cancer due to its role in folate transport and tumor progression. This Phase I study evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of mirvetuximab soravtansine (MIRV), an antibody-drug conjugate targeting FRα, in Chinese patients with FRα-overexpressed platinum-resistant advanced ovarian cancer.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/safety-tolerability-and-pharmacokinetics-of-mirvetuximab-soravtansine-in-chinese-patients-with-folate-receptor-positive-advanced-ovarian-cancer/354274/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/safety-tolerability-and-pharmacokinetics-of-mirvetuximab-soravtansine-in-chinese-patients-with-folate-receptor-positive-advanced-ovarian-cancer/354274.png","ImageObject",300,407,{"name":42,"@type":43},"Dipper","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of this Phase I study?","Question",{"text":63,"@type":64},"To assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of mirvetuximab soravtansine in Chinese patients with FRα-overexpressed platinum-resistant advanced ovarian cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was MIRV administered in this trial?",{"text":68,"@type":64},"Patients received MIRV in escalating doses from 5 to 6 mg/kg using a 3+3 dose-escalation design, followed by dose expansion (5 mg/kg cohort n=4; 6 mg/kg cohort n=15).",{"name":70,"@type":61,"acceptedAnswer":71},"What did the study report about safety, pharmacokinetics, and efficacy?",{"text":72,"@type":64},"Grade ≥3 adverse events included decreased platelet count, decreased lymphocyte count, and anemia; pharmacokinetics showed Tmax around 3.33 h and a terminal half-life around 118 h; objective response rate was 26.7% among efficacy-evaluable high-grade serous patients, with partial responses and stable disease reported.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},354274,1790192939,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},1374404997633,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Cancer Medicine  \nRESEARCH ARTICLE  OPEN ACCESS   \nSafety, Tolerability, and Pharmacokinetics of Mirvetuximab Soravtansine in Chinese Patients With Folate Receptor α-Positive Advanced Ovarian Cancer  \nYongsheng Li1  | Li Yuan1  | Ge Lou2 | Hongbing Cai3 | Yuzhi Li4 | Fenghu Li5 | Li Wang6 | Xingtao Long1 | Yi Gong1 | Chaonan Zhu7 | Li Li7 | June Xu7 | Qi Zhou1  \n1Chongqing University Cancer Hospital, Chongqing, China | 2Harbin Medical University Cancer Hospital, Harbin, China | 3Zhongnan Hospital of Wuhan University, Wuhan, China | 4The First Affiliated Hospital of Bengbu Medical College, Bengbu, China | 5Guizhou Provincial Cancer Hospital, Guiyang, China | 6Henan Cancer Hospital, Zhengzhou, China | 7Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd, Hangzhou, China  \nCorrespondence: Qi Zhou ([qizhou9128@163.com](qizhou9128@163.com))  \nReceived: 17 February 2025 | Revised: 30 November 2025 | Accepted: 23 February 2026  \nKeywords: antibody drug conjugate | mirvetuximab soravtansine | refractory ovarian cancer | targeted therapy  \nABSTRACT  \nBackground: Folate receptor α (FRα) is a glycosylphosphatidylinositol-anchored protein that facilitates folate transport and has emerged as a promising therapeutic target for ovarian cancer, particularly due to its association with tumor progression. This Phase I study investigated the safety, tolerability, pharmacokinetics, and preliminary efficacy of mirvetuximab soravtansine (MIRV), an antibody-drug conjugate targeting folate receptor α (FRα), in Chinese patients with FRα-overexpressed platinumresistant ovarian cancer.  \nMethods: This study enrolled 19 Chinese patients with previously treated FRα-overexpressed ovarian cancer in the dose escalation phase (5 mg/kg, n = 4; 6 mg/kg, n = 3) and dose expansion phase (n = 12). MIRV was administered in escalating doses from 5 to 6 mg/kg (adjusted ideal body weight), following a 3 + 3 dose-escalation design. The trial is registered with chinadrugtrials. [org.cn](org.cn) (CTR20211876).  \nResults: Median treatment exposure were 9.9 weeks for the 5 mg/kg cohort (n = 4) and 13.1 weeks for the 6 mg/kg cohort (n = 15) . The most common grade ≥3 adverse events were decreased platelet count (21.1%), decreased lymphocyte count (15.8%), and anemia (15.8%) . The plasma concentration-time and pharmacokinetic profiles of MIRV and the total antibody were generally comparable after the first and third doses. Pharmacokinetic analysis revealed a median time to maximum concentration (Tmax) of 3.33 h, mean terminal half-life (T1/2) of 118 h, and geometric mean maximum concentration (Cmax) of 137.07 μg/mL. MIRV exposures were comparable to those reported in Caucasian patients. No anti-drug antibodies were detected. Among 15 efficacyevaluable patients with high-grade serous ovarian cancer, the objective response rate was 26.7%, with partial responses in four patients and stable disease in seven patients.  \nConclusions: MIRV showed anticipated pharmacokinetics, safety, tolerability, and efficacy profiles in Chinese patients with FRα -positive platinum-resistant ovarian cancers, supporting its potential as a targeted therapeutic agent for this patient population. Trial Registration: The trial is [registered with](registered with chinadrugtrials.org.cn)[ chinadrugtrials.org.cn](registered with chinadrugtrials.org.cn) (CTR20211876)  \n\n| Yongsheng Li and Li Yuan contributed equally and should be regarded as co-first authors. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.\u003Cbr>© 2026 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd. |\n\nCancer Medicine, 2026; 15:e71704 1 of 12  \n[https://doi.org/10.1002/cam4.71704](https://doi.org/10.1002/cam4.71704)  \n1 | Introduction  \nOvarian cancer ranks as the third most common yet the most lethal gynecological malignancy [1] . Annually, both the global incid","cbCaiuQYtF3BxSqc","https://ap.wps.com/l/cbCaiuQYtF3BxSqc","pdf",1300370,12,"English","# Introduction\n## Disease burden and diagnostic challenges\n# Study design and treatment\n## Dose escalation and expansion approach\n# Results\n## Safety and adverse events\n## Pharmacokinetic parameters\n## Anti-drug antibodies and preliminary efficacy\n# Conclusion","[{\"question\":\"What is the main purpose of this Phase I study?\",\"answer\":\"To assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of mirvetuximab soravtansine in Chinese patients with FRα-overexpressed platinum-resistant advanced ovarian cancer.\"},{\"question\":\"How was MIRV administered in this trial?\",\"answer\":\"Patients received MIRV in escalating doses from 5 to 6 mg/kg using a 3+3 dose-escalation design, followed by dose expansion (5 mg/kg cohort n=4; 6 mg/kg cohort n=15).\"},{\"question\":\"What did the study report about safety, pharmacokinetics, and efficacy?\",\"answer\":\"Grade ≥3 adverse events included decreased platelet count, decreased lymphocyte count, and anemia; pharmacokinetics showed Tmax around 3.33 h and a terminal half-life around 118 h; objective response rate was 26.7% among efficacy-evaluable high-grade serous patients, with partial responses and stable disease reported.\"}]","Safety, Tolerability, and Pharmacokinetics of Mirvetuximab Soravtansine in Chinese Patients With Folate Receptor α-Positive Advanced Ovarian Cancer | PDF",1790109816,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8844997beeeaec393c64fe6e5f3d8629.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2c27fc8d7cdef6f040c05984e94523da.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/03196742065ea0e096aca1c8bccd0815.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/04be9e7504436717043901f9b2d217fc.webp",980,1287]